Read the article. Two different professors are quoted as saying it reduces effectiveness. That would qualify as resistant...
According to Shabir Madhi, a professor of vaccinology who is leading trials of the Oxford-AstraZeneca vaccine in South Africa, the mutated variant of the virus might "weaken the impact" of vaccines.
John Bell, a professor who led the development of the AstraZeneca-University of Oxford COVID-19 vaccine, has also voiced concern about the effectiveness of current vaccines on the 501Y.V2 variant.
"The mutations associated with the South African form are really pretty substantial changes in the structure of the protein. The protein has a domain, which binds to the human cells—it's called the receptor-binding domain, and it's where the virus attaches itself," he said on Sunday.
"If you get an immune response that protects you, one of the ways it protects you is it gets in the way of that binding event. So you rely on antibodies to bind to that domain to stop the virus from binding onto yourself. That's basically the whole basis for vaccines. If you get an infection, you make antibodies to that domain that prevent you getting reinfected."